Literature DB >> 19837292

Smallpox vaccines for biodefense.

Richard B Kennedy1, Inna Ovsyannikova, Gregory A Poland.   

Abstract

Few diseases can match the enormous impact that smallpox has had on mankind. Its influence can be seen in the earliest recorded histories of ancient civilizations in Egypt and Mesopotamia. With fatality rates up to 30%, smallpox left its survivors with extensive scarring and other serious sequelae. It is estimated that smallpox killed 500 million people in the 19th and 20th centuries. Given the ongoing concerns regarding the use of variola as a biological weapon, this review will focus on the licensed vaccines as well as current research into next-generation vaccines to protect against smallpox and other poxviruses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837292      PMCID: PMC2764553          DOI: 10.1016/j.vaccine.2009.07.103

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  124 in total

1.  Clinical responses to undiluted and diluted smallpox vaccine.

Authors:  Sharon E Frey; Robert B Couch; Carol O Tacket; John J Treanor; Mark Wolff; Frances K Newman; Robert L Atmar; Robert Edelman; Carrie M Nolan; Robert B Belshe
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

Review 2.  The formation and function of extracellular enveloped vaccinia virus.

Authors:  Geoffrey L Smith; Alain Vanderplasschen; Mansun Law
Journal:  J Gen Virol       Date:  2002-12       Impact factor: 3.891

3.  Of smallpox and empire. [Review of: Fenn, EA. Pox Americana: the great smallpox epidemic of 1775-82. New York: Hill and Wang, 2001].

Authors:  Carol R Byerly
Journal:  Rev Am Hist       Date:  2002-06

4.  Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector.

Authors:  Koji Ishii; Yoshiaki Ueda; Kazuhiro Matsuo; Yoshiharu Matsuura; Takashi Kitamura; Kenzo Kato; Yasuyuki Izumi; Kenji Someya; Takeaki Ohsu; Mitsuo Honda; Tatsuo Miyamura
Journal:  Virology       Date:  2002-10-25       Impact factor: 3.616

5.  DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.

Authors:  J W Hooper; D M Custer; C S Schmaljohn; A L Schmaljohn
Journal:  Virology       Date:  2000-01-20       Impact factor: 3.616

6.  Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.

Authors:  D F Smee; K W Bailey; M H Wong; R W Sidwell
Journal:  Antiviral Res       Date:  2001-10       Impact factor: 5.970

7.  Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.

Authors:  M Bray; M Martinez; D F Smee; D Kefauver; E Thompson; J W Huggins
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

Review 8.  Smallpox: a potential agent of bioterrorism.

Authors:  Richard J Whitley
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 5.970

9.  Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.

Authors:  B T Ober; P Brühl; M Schmidt; V Wieser; W Gritschenberger; S Coulibaly; H Savidis-Dacho; M Gerencer; F G Falkner
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Developing new smallpox vaccines.

Authors:  S R Rosenthal; M Merchlinsky; C Kleppinger; K L Goldenthal
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more
  21 in total

1.  Correlations between vaccinia-specific immune responses within a cohort of armed forces members.

Authors:  Benjamin J Umlauf; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2011-09-29       Impact factor: 2.257

2.  A viral, transporter associated with antigen processing (TAP)-independent, high affinity ligand with alternative interactions endogenously presented by the nonclassical human leukocyte antigen E class I molecule.

Authors:  Elena Lorente; Susana Infantes; David Abia; Eilon Barnea; Ilan Beer; Ruth García; Fátima Lasala; Mercedes Jiménez; Carmen Mir; Antonio Morreale; Arie Admon; Daniel López
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

3.  Impaired innate, humoral, and cellular immunity despite a take in smallpox vaccine recipients.

Authors:  Richard B Kennedy; Gregory A Poland; Inna G Ovsyannikova; Ann L Oberg; Yan W Asmann; Diane E Grill; Robert A Vierkant; Robert M Jacobson
Journal:  Vaccine       Date:  2016-05-11       Impact factor: 3.641

4.  Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells.

Authors:  Elena Lorente; Susana Infantes; Eilon Barnea; Ilan Beer; Ruth García; Fátima Lasala; Mercedes Jiménez; Carlos Vilches; François A Lemonnier; Arie Admon; Daniel López
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

5.  The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry.

Authors:  Chwan Hong Foo; J Charles Whitbeck; Manuel Ponce-de-León; Wan Ting Saw; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

Review 6.  Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.

Authors:  Lynette Siv Chea; Rama Rao Amara
Journal:  Expert Rev Vaccines       Date:  2017-09-04       Impact factor: 5.217

7.  The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.

Authors:  Richard B Kennedy; Gregory A Poland
Journal:  Virology       Date:  2010-10-18       Impact factor: 3.616

Review 8.  Vaccinia virus-based vector against infectious diseases and tumors.

Authors:  Ziling Zhang; Lanlan Dong; Chen Zhao; Peiyong Zheng; Xiaoyan Zhang; Jianqing Xu
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

9.  Zoonotic vaccinia virus strains belonging to different genetic clades exhibit immunomodulation abilities that are proportional to their virulence.

Authors:  Karine Lima Lourenço; Leandro Andrade Chinália; Lethícia Ribeiro Henriques; Rodrigo Araújo Lima Rodrigues; Flávio Guimarães da Fonseca
Journal:  Virol J       Date:  2021-06-09       Impact factor: 4.099

10.  L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines.

Authors:  Sole Maria Pacchioni; Massimiliano Bissa; Carlo Zanotto; Carlo De Giuli Morghen; Elena Illiano; Antonia Radaelli
Journal:  J Transl Med       Date:  2013-04-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.